ExodusPoint Capital Management’s Lifecore Biomedical LFCR Stock Holding History

ExodusPoint Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,932	Closed	-$117K	–	1818
2025 Q3	$117K	Buy	+15,932	New	+$121K	﹤0.01%	1418
2024 Q4	–	Sell	-41,529	Closed	-$205K	–	1799
2024 Q3	$205K	Buy	+41,529	New	+$217K	﹤0.01%	1450
2024 Q1	–	Sell	-18,700	Closed	-$116K	–	1750
2023 Q4	$116K	Buy	+18,700	New	+$130K	﹤0.01%	1343
2021 Q3	–	Sell	-12,369	Closed	-$139K	–	2401
2021 Q2	$139K	Buy	+12,369	New	+$143K	﹤0.01%	2078
2020 Q3	–	Sell	-37,678	Closed	-$300K	–	2012
2020 Q2	$300K	Buy	+37,678	New	+$389K	0.01%	1322
2019 Q4	–	Sell	-17,505	Closed	-$190K	–	1721
2019 Q3	$190K	Buy	+17,505	New	+$191K	0.01%	1139

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

ExodusPoint Capital Management's LFCR Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Lifecore Biomedical (LFCR) in Q4 2025, closing a stake of 15,932 shares — an estimated $117K sold.

ExodusPoint Capital Management first reported a position in LFCR in Q3 2019 and held it in 6 quarters. The position peaked at $300K in Q2 2020. 103 funds tracked by Wall St. Rank hold LFCR as of Q4 2025.

ExodusPoint Capital Management reported no remaining Lifecore Biomedical position as of Q4 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 15,932 Lifecore Biomedical shares in Q4 2025, an estimated $117K.
ExodusPoint Capital Management first reported a position in Lifecore Biomedical in Q3 2019 and held it in 6 quarters.
ExodusPoint Capital Management's Lifecore Biomedical position peaked at $300K in Q2 2020.
103 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.